Rifapentine (RPT) — Competitive Intelligence Brief

Rifapentine (RPT) (Rifapentine (RPT)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rifamycin antibiotic. Area: Infectious Disease.

phase 3 Rifamycin antibiotic Bacterial RNA polymerase Infectious Disease Small molecule

Target snapshot

Rifapentine (RPT) (Rifapentine (RPT)) — Walter K. Kraft. Rifapentine inhibits bacterial RNA polymerase, preventing transcription and killing or stopping the growth of mycobacteria.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rifapentine (RPT) TARGET	Rifapentine (RPT)	Walter K. Kraft	phase 3	Rifamycin antibiotic	Bacterial RNA polymerase
Vancomycin plus Rifampin	Vancomycin plus Rifampin	Michael E. DeBakey VA Medical Center	marketed	Antibiotic combination	Bacterial cell wall (vancomycin) and bacterial RNA polymerase (rifampin)
Rifaximin oral tablet	Rifaximin oral tablet	Yokohama City University	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
Rifaximin and loperamide	Rifaximin and loperamide	The University of Texas Health Science Center, Houston	marketed	Antibiotic + antidiarrheal combination	Bacterial RNA polymerase (rifaximin); mu-opioid receptors in the GI tract (loperamide)
Rifampicin alone	Rifampicin alone	Miguel Santín	marketed	Rifamycin antibiotic	Bacterial RNA polymerase β-subunit
Rifampicin Capsules	Rifampicin Capsules	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
Rifampin/isoniazid FDC	Rifampin/isoniazid FDC	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antituberculous agent (fixed-dose combination)	Bacterial RNA polymerase (rifampin); mycolic acid biosynthesis (isoniazid)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rifamycin antibiotic class)

1. Institute of Tropical Medicine, Belgium · 2 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
3. National Taiwan University Hospital · 2 drugs in this class
4. Bausch Health Americas, Inc. · 2 drugs in this class
5. South China Children's Leukemia Group · 1 drug in this class
6. Suzhou Zelgen Biopharmaceuticals Co.,Ltd · 1 drug in this class
7. TenNor Therapeutics (Suzhou) Limited · 1 drug in this class
8. The University of Texas Health Science Center at Tyler · 1 drug in this class
9. University College, London · 1 drug in this class
10. University of California, San Francisco · 1 drug in this class